Trials / Completed
CompletedNCT00721578
A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections
An Observational Study Of Patients Receiving Therapy For Systemic Fungal Infections
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 23 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To collect and summarize information on the diagnosis, management, and clinical and mycological outcomes of patients with systemic fungal infections in order to better understand the effectiveness of antifungals in the treatment of Systemic Fungal Infections (SFI) in India.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | voriconazole | Patients must have received (in the Intensive Care Unit \[ICU\] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study. |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2008-07-24
- Last updated
- 2011-01-10
- Results posted
- 2010-08-26
Locations
3 sites across 1 country: India
Source: ClinicalTrials.gov record NCT00721578. Inclusion in this directory is not an endorsement.